论文部分内容阅读
小剂量BEAM(卡氮芥、VP16、Ara-C及白消安)与ESHAP(顺铂、VP16、甲泼尼龙和大剂量Ara-C)是治疗非霍奇金淋巴瘤(NHL)的两种非交叉耐药方案,为了解联合交替应用这两种方案治疗难治性NHL的有效性,作者选择一组病例进行了研究。 28例成年难治性NHL患者,中位年龄51岁,男23例,女5例。组织学分类高、中、低度恶性分别为7、18、3侧。应用BEAM/ESHAP方案时临床分期Ⅰ/Ⅱ期5例、Ⅲ期5例、Ⅳ期18例。均曾接受过其他方案化疗。
Low-dose BEAM (calcium mustard, VP16, Ara-C, and busulfan) and ESHAP (cisplatin, VP16, methylprednisolone, and high-dose Ara-C) are two types of treatment for non-Hodgkin’s lymphoma (NHL) For the non-cross-resistance regimen, the authors selected a group of cases for the purpose of understanding the effectiveness of the two alternative regimens for the treatment of refractory NHL. Twenty-eight adult patients with refractory NHL had a median age of 51 years, 23 men and 5 women. The histological classification of high, medium and low grades were 7, 18, and 3, respectively. When the BEAM/ESHAP protocol was used, there were 5 clinical stage I/II stages, 5 stage III stages, and 18 stage IV stages. Have received other regimen chemotherapy.